FGF1 and type 2 diabetes mellitus: While further preclinical and clinical assessments are warranted to fully elucidate long-term safety and efficacy, these engineered FGF1 proteins represent highly promising candidates for a new generation of protein-based drugs to combat type 2 diabetes.